ADEPTRIX CORP
1 known investors
Adeptrix develops the exoBAMS platform, using antibody-based immunoaffinity capture of extracellular vesicles combined with MALDI mass spectrometry to profile proteins, lipids, metabolites and other molecules from a single blood sample. It provides custom assay development and bioanalytical services to researchers for biomarker discovery, disease-signature analysis, and translational research in oncology, neurology, and other disease areas.
AI & Machine LearningBiotechMedical Devices
Investors · 1
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Science Foundation | Phase II | 2015 | $750K |
| National Science Foundation | Phase I | 2013 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $698.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does ADEPTRIX CORP do?
- Adeptrix develops the exoBAMS platform, using antibody-based immunoaffinity capture of extracellular vesicles combined with MALDI mass spectrometry to profile proteins, lipids, metabolites and other molecules from a single blood sample. It provides custom assay development and bioanalytical services to researchers for biomarker discovery, disease-signature analysis, and translational research in oncology, neurology, and other disease areas.
- Who are ADEPTRIX CORP's investors?
- ADEPTRIX CORP's investors include Formation Venture Engineering.